Clinical Trial Update: Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating vorinostat and bortezomib as third-line therapy in advanced non-small cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Carcinoma

Drugs mentioned

• Bortezomib (bortezomib)
• Vorinostat (vorinostat)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Carcinoma, Non Small Cell Lung | Phase 2 | Status: COMPLETED | Results posted: 2016-11-21